

**ERYTECH PHARMA**

*Société Anonyme* company with a share capital of 688 276,10 euros  
Headquarters : 60 Avenue Rockefeller, Bâtiment Adénine, 69008 LYON - FRANCE  
479 560 013 RCS LYON

PURSUANT TO ARTICLE R.225-83 5° of the French *Code de commerce*  
NOMINATION TO THE BOARD OF DIRECTORS

**MIXED GENERAL SHAREHOLDERS' MEETING OF 23 JUNE 2015**

Name : DOCHEZ

First Name : Luc

Age : 40 years old

Professional references :

- Luc Dochez, has served as Chief Business Officer and Senior Vice-President of Business Development of Prosensa (NASDAQ: RNA) since November 2008 until its recent acquisition by Biomarin. At Prosensa, Luc has been instrumental in signing a >\$500M licensing deal with GSK, he has been actively involved in the successful listing on NASDAQ and he has managed the process leading to the acquisition of the company by BioMarin for \$860M. Mr. Dochez has over 15 years of experience in the biotechnology industry. Before joining Prosensa, he was a consultant within Arthur D. Little's biotechnology practice, Director of Business Development at Methexis Genomics, Vice President of Business Development at TiGenix N.V. and President of TiGenix Inc. Mr. Dochez holds a Pharm.D. degree from the University of Leuven , a postgraduate degree in business economics from the same university and an M.B.A. degree from Vlerick Management School.

Position in the company:

- None

Positions in other companies:

- Managing Director of Primix Bioventures BVBA
- Executive Officer of Tusk Therapeutics NV

Position occupied in the last five years:

- Managing Director / Business Director of Prosensa Holding NV
- Director of the board of Ovizio SA
- Director of the board of Arcarios BV

Number of shares held on 12/31/2014 : 0 share

The Chief Executive Officer